In this issue:
Tagraxofusp monotherapy has modest clinical activity
Encouraging anti-fibrotic activity for PXS-5505
Routine blood testing may aid in the diagnosis of pre-fibrotic myelofibrosis
European LeukemiaNet criteria for evaluation of new drugs
FIBROMET: metformin is a promising adjuvant therapy
Flonoltinib maleate outperforms ruxolitinib in Chinese trial
MANIFEST-2: Durable benefit to front-line pelabresib + ruxolitinib
Calreticulin-specific antibody promising for CALR mutated myelofibrosis
Nuvisertib + momelotinib for relapsed/ refractory myelofibrosis
Please login below to download this issue (PDF)